It is recommended that Dacarbazine for Injection be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents.
- Hemopoietic depression is the most common toxicity with Dacarbazine for Injection (see WARNINGS).
- Hepatic necrosis has been reported (see WARNINGS).
- Studies have demonstrated this agent to have a carcinogenic and teratogenic effect when used in animals.
- In treatment of each patient, the physician must weigh carefully the possibility of achieving therapeutic benefit against the risk of toxicity.